Pulmatrix, Inc. (PULM)
1.55
+0.16
(+11.11%)
USD |
NASDAQ |
Sep 09, 14:00
Pulmatrix EPS Diluted (Quarterly) : -0.288 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.288 |
| March 31, 2026 | -0.3209 |
| December 31, 2025 | -0.2541 |
| September 30, 2025 | -0.2401 |
| June 30, 2025 | -0.4241 |
| March 31, 2025 | -0.495 |
| December 31, 2024 | -0.5438 |
| September 30, 2024 | -0.7083 |
| June 30, 2024 | -1.591 |
| March 31, 2024 | 0.2259 |
| December 31, 2023 | -0.5703 |
| September 30, 2023 | -1.033 |
| June 30, 2023 | -1.045 |
| March 31, 2023 | -1.218 |
| December 31, 2022 | -1.158 |
| September 30, 2022 | -1.452 |
| June 30, 2022 | -1.363 |
| March 31, 2022 | -1.508 |
| December 31, 2021 | -2.243 |
| September 30, 2021 | -2.91 |
| June 30, 2021 | -1.370 |
| March 31, 2021 | -1.783 |
| December 31, 2020 | -1.606 |
| September 30, 2020 | -6.221 |
| June 30, 2020 | -0.96 |
| Date | Value |
|---|---|
| March 31, 2020 | -4.579 |
| December 31, 2019 | -4.042 |
| September 30, 2019 | -3.503 |
| June 30, 2019 | -8.164 |
| March 31, 2019 | -14.85 |
| December 31, 2018 | -17.59 |
| September 30, 2018 | -20.53 |
| June 30, 2018 | -26.00 |
| March 31, 2018 | -48.00 |
| December 31, 2017 | -42.00 |
| September 30, 2017 | -44.00 |
| June 30, 2017 | -58.00 |
| March 31, 2017 | -42.00 |
| December 31, 2016 | -132.00 |
| September 30, 2016 | -42.00 |
| June 30, 2016 | -124.00 |
| March 31, 2016 | -76.00 |
| December 31, 2015 | -62.50 |
| September 30, 2015 | -68.00 |
| June 30, 2015 | -532.00 |
| March 31, 2015 | -285.00 |
| March 31, 2014 | -230.30 |
| December 31, 2013 | -70.76 |
| September 30, 2013 | -60.00 |
| June 30, 2013 | -30.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.036M |
| Total Expenses (Quarterly) | 1.036M |
| Enterprise Value | 3.193M |
| Earnings Yield | -71.17% |
| Normalized Earnings Yield | -71.17 |